This Month:

"Enhanced suppressive function of regulatory T cells from patients with immune-mediated diseases following successful ex vivo expansion", From Tinghua Cao, Sally E. Wenzel, William A. Faubion, Gregory Harriman and Li Li.

Full article PDF freely accessible

TINGHUA CAO, Ph.D.
Senior Research Scientist, Immunology Research, Centocor R&D, Johnson & Johnson
Senior Research Scientist, Therakos/OCD, Johnson & Johnson, 2005-2009
Postdoctoral Associate, Baylor Institute for Immunology Research, 2002-2005
Ph.D. in Immunology, Center for Vaccinology, University of Gent, Belgium, 1996-2001
MS/BS, Hubei Medical University, Wuhan, China (1980-1990)

RESEARCH INTERESTS:

• Regulatory T cell biology and therapy;
• Dendritic cell biology and therapy,
• Cellular immunology (Th1/Th2/Th17)
• Autoimmunity/Cancer immunology/Anti-viral immunity/Vaccinology

After my immunology training in Baylor Institute for Immunology Research (Dallas, TX) and Center for Vaccinology, University of Ghent, Belgium, my current research interests are to study immunopathogeneic mechanisms of autoimmune and inflammatory diseases and develop new immunological therapy for autoimmunity. In past years, we had focused on the studies of Treg biology and development of Treg therapy for autoimmune diseases. Hopefully the technical challenges for this new potential therapy will be resolved in a few years, and be moved forward to clinical trial.

CONTACT INFORMATION
Email: tcao4@its.jnj.com; or tinghuacao@hotmail.com
Tel: 610-651-6748

Access the full article on ScienceDirect